Asymchem Laboratories Tian Jin Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 5.07%

Asymchem Laboratories Tian Jin Co Ltd (002821) has an Asset Resilience Ratio of 5.07% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥1.05 Billion
≈ $153.46 Million USD Cash + Short-term Investments

Total Assets

CN¥20.70 Billion
≈ $3.03 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how Asymchem Laboratories Tian Jin Co Ltd's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Asymchem Laboratories Tian Jin Co Ltd to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Asymchem Laboratories Tian Jin Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Asymchem Laboratories Tian Jin Co Ltd market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥1.05 Billion 5.07%
Total Liquid Assets CN¥1.05 Billion 5.07%

Asset Resilience Insights

  • Limited Liquidity: Asymchem Laboratories Tian Jin Co Ltd maintains only 5.07% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Asymchem Laboratories Tian Jin Co Ltd Industry Peers by Asset Resilience Ratio

Compare Asymchem Laboratories Tian Jin Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Akero Therapeutics Inc
NASDAQ:AKRO
Biotechnology 55.87%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Zealand Pharma A/S
CO:ZEAL
Biotechnology 63.98%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Immunitybio Inc
NASDAQ:IBRX
Biotechnology 38.07%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%

Annual Asset Resilience Ratio for Asymchem Laboratories Tian Jin Co Ltd (2013–2025)

The table below shows the annual Asset Resilience Ratio data for Asymchem Laboratories Tian Jin Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 5.51% CN¥1.12 Billion
≈ $163.39 Million
CN¥20.28 Billion
≈ $2.97 Billion
-2.48pp
2024-12-31 7.98% CN¥1.54 Billion
≈ $225.32 Million
CN¥19.29 Billion
≈ $2.82 Billion
-1.66pp
2023-12-31 9.64% CN¥1.91 Billion
≈ $278.88 Million
CN¥19.77 Billion
≈ $2.89 Billion
-2.15pp
2022-12-31 11.79% CN¥2.15 Billion
≈ $314.77 Million
CN¥18.24 Billion
≈ $2.67 Billion
+9.15pp
2021-12-31 2.65% CN¥401.20 Million
≈ $58.71 Million
CN¥15.16 Billion
≈ $2.22 Billion
+2.42pp
2018-12-31 0.22% CN¥7.11 Million
≈ $1.04 Million
CN¥3.19 Billion
≈ $466.12 Million
-2.06pp
2015-12-31 2.28% CN¥29.01 Million
≈ $4.25 Million
CN¥1.27 Billion
≈ $186.06 Million
+2.27pp
2014-12-31 0.01% CN¥88.56K
≈ $12.96K
CN¥1.06 Billion
≈ $154.84 Million
-0.05pp
2013-12-31 0.06% CN¥502.60K
≈ $73.55K
CN¥913.19 Million
≈ $133.63 Million
--
pp = percentage points

About Asymchem Laboratories Tian Jin Co Ltd

SHE:002821 China Biotechnology
Market Cap
$7.44 Billion
CN¥50.82 Billion CNY
Market Cap Rank
#2724 Global
#325 in China
Share Price
CN¥152.65
Change (1 day)
+4.59%
52-Week Range
CN¥89.50 - CN¥195.75
All Time High
CN¥358.21
About

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more